1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow John Reneau: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Cyclophosphamide, Fludarabine, Mogamulizumab - Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | John Reneau | 12 | 2022-05-06 | 2026-11-16 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
Lymphoma, T-Cell, Cutaneous (2) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (1) · Lymphoma, T-Cell (1) · Lymphomatoid Papulosis (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Brentuximab Vedotin (1) · Cyclophosphamide (1) · Disulfides (1) · Immunoglobulin G (1) · Lenalidomide (1) · fludarabine (1) · mogamulizumab (1)
United States (2)